Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins, AmpTec to Co-market Synthetic RNAs

NEW YORK (GenomeWeb) — Eurofins Genomics and AmpTec have agreed to non-exclusively co-market AmptTec's IVT-RNAs globally under a deal announced today.

The co-marketing agreement covers in vitro transcribed single-stranded, double-stranded, and functional synthetic mRNAs that can be used in a variety of applications including in vitro diagnostics of pathogens, rare mutation detection, and companion diagnostics, Eurofins said.

Together the companies will offer custom services for synthetic genes and very long synthetic RNAs to an international market, Eurofins added.

"The cooperation will allow us to broaden Eurofins' portfolio with innovative nucleic acid products," Bruno Poddevin, senior vice president of Eurofins Genomics, said in a statement. "By sharing best practices, clients will benefit from an unparalleled spectrum of custom services for IVT-RNAs, which in turn should fuel further market share growth for both partners."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.